Home > Drugs A – Z > Cladribine (By injection)

Cladribine (By injection)

Treats certain kinds of leukemia.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Cladribine belongs to the group of medicines called antimetabolites. It is used to treat hairy cell leukemia, a cancer of the blood and bone marrow. It is also sometimes used to treat other kinds of cancer, as determined by your doctor. Cladribine interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by cladribine,… Read more
Brand names include
Cladribine Novaplus, Leustatin
Drug classes About this
Antineoplastic Agent

What works? Research summarized

Evidence reviews

Purine Antagonists for Chronic Lymphocytic Leukaemia

Despite increasing insight into its tumour biology B‐CLL remains an incurable disease. So far, chemotherapy with alkylating agents such as chlorambucil has been the mainstay of treatment in B‐CLL. However, purine antagonists such as fludarabine are increasingly being used, as it has been suggested that these novel drugs are more effective. This review confirms the greater response rates achievable by using purine antagonists but at the cost of greater toxicity, mainly infections. There is inconclusive evidence whether treatment with purine antagonists improves survival. None of the studies included quality of life data. More research is needed to fully explore the role of purine antagonists in the treatment of B‐CLL and their potential impact on survival.

Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet]

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that is more common in women than in men, by a factor of approximately 3:1. Canada has the fifth-highest worldwide prevalence at 240 per 100,000 persons.

Disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Sufficient data were available from 22 studies on the following drugs: cladribine (Movectro), glatiramer acetate (Copaxone), interferon beta‐1b (Betaferon), interferon beta‐1a (Rebif; Avonex), and teriflunomide (Aubagio).

See all (10)

Summaries for consumers

Purine Antagonists for Chronic Lymphocytic Leukaemia

Despite increasing insight into its tumour biology B‐CLL remains an incurable disease. So far, chemotherapy with alkylating agents such as chlorambucil has been the mainstay of treatment in B‐CLL. However, purine antagonists such as fludarabine are increasingly being used, as it has been suggested that these novel drugs are more effective. This review confirms the greater response rates achievable by using purine antagonists but at the cost of greater toxicity, mainly infections. There is inconclusive evidence whether treatment with purine antagonists improves survival. None of the studies included quality of life data. More research is needed to fully explore the role of purine antagonists in the treatment of B‐CLL and their potential impact on survival.

Disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Sufficient data were available from 22 studies on the following drugs: cladribine (Movectro), glatiramer acetate (Copaxone), interferon beta‐1b (Betaferon), interferon beta‐1a (Rebif; Avonex), and teriflunomide (Aubagio).

Hairy Cell Leukemia Treatment (PDQ®): Patient Version

Expert-reviewed information summary about the treatment of hairy cell leukemia.

See all (4)

PubMed Health Blog...

read all...